<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20240411222019&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20240411222019&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 12 Apr 2024 02:20:21 +0000</lastbuilddate>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Unveiling Platelets as Immune Regulatory Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38603477/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 12;134(8):987-989. doi: 10.1161/CIRCRESAHA.124.324167. Epub 2024 Apr 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38603477/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38603477</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324167>10.1161/CIRCRESAHA.124.324167</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38603477</guid>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Danielle Karakas</dc:creator>
<dc:creator>Heyu Ni</dc:creator>
<dc:date>2024-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Unveiling Platelets as Immune Regulatory Cells</dc:title>
<dc:identifier>pmid:38603477</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324167</dc:identifier>
</item>
<item>
<title>AKAP12 Overexpression Affects Cardiac Function via PDE8</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38603476/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 12;134(8):1023-1025. doi: 10.1161/CIRCRESAHA.124.324475. Epub 2024 Apr 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38603476/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38603476</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324475>10.1161/CIRCRESAHA.124.324475</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38603476</guid>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Hariharan Subramanian</dc:creator>
<dc:creator>Viacheslav O Nikolaev</dc:creator>
<dc:date>2024-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>AKAP12 Overexpression Affects Cardiac Function via PDE8</dc:title>
<dc:identifier>pmid:38603476</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324475</dc:identifier>
</item>
<item>
<title>Correction to: Circadian Rhythms of the Blood-Brain Barrier and Drug Delivery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38603475/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 12;134(8):e92. doi: 10.1161/RES.0000000000000668. Epub 2024 Apr 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38603475/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38603475</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000668>10.1161/RES.0000000000000668</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38603475</guid>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: Circadian Rhythms of the Blood-Brain Barrier and Drug Delivery</dc:title>
<dc:identifier>pmid:38603475</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000668</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38603474/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 12;134(8):952-953. doi: 10.1161/RES.0000000000000670. Epub 2024 Apr 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38603474/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38603474</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000670>10.1161/RES.0000000000000670</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38603474</guid>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38603474</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000670</dc:identifier>
</item>
<item>
<title>Environmental Exposome and Atrial Fibrillation: Emerging Evidence and Future Directions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38603473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>There has been increased awareness of the linkage between environmental exposures and cardiovascular health and disease. Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting millions of people worldwide and contributing to substantial morbidity and mortality. Although numerous studies have explored the role of genetic and lifestyle factors in the development and progression of atrial fibrillation, the potential impact of environmental determinants on this prevalent...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 12;134(8):1029-1045. doi: 10.1161/CIRCRESAHA.123.323477. Epub 2024 Apr 11.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There has been increased awareness of the linkage between environmental exposures and cardiovascular health and disease. Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting millions of people worldwide and contributing to substantial morbidity and mortality. Although numerous studies have explored the role of genetic and lifestyle factors in the development and progression of atrial fibrillation, the potential impact of environmental determinants on this prevalent condition has received comparatively less attention. This review aims to provide a comprehensive overview of the current evidence on environmental determinants of atrial fibrillation, encompassing factors such as air pollution, temperature, humidity, and other meteorologic conditions, noise pollution, greenspace, and the social environment. We discuss the existing evidence from epidemiological and mechanistic studies, critically evaluating the strengths and limitations of these investigations and the potential underlying biological mechanisms through which environmental exposures may affect atrial fibrillation risk. Furthermore, we address the potential implications of these findings for public health and clinical practice and identify knowledge gaps and future research directions in this emerging field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38603473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38603473</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323477>10.1161/CIRCRESAHA.123.323477</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38603473</guid>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Sojin Youn Wass</dc:creator>
<dc:creator>Omar Hahad</dc:creator>
<dc:creator>Zain Asad</dc:creator>
<dc:creator>Shuo Li</dc:creator>
<dc:creator>Mina K Chung</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:creator>Sadeer G Al-Kindi</dc:creator>
<dc:date>2024-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Environmental Exposome and Atrial Fibrillation: Emerging Evidence and Future Directions</dc:title>
<dc:identifier>pmid:38603473</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323477</dc:identifier>
</item>
<item>
<title>Patient-Centered Adult Cardiovascular Care: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38602110/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>Patient-centered care is gaining widespread acceptance by the medical and lay communities and is increasingly recognized as a goal of high-quality health care delivery. Patient-centered care is based on ethical principles and aims at establishing a partnership between the health care team and patient, family member, or both in the care planning and decision-making process. Patient-centered care involves providing respectful care by tailoring management decisions to patients' beliefs,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 11. doi: 10.1161/CIR.0000000000001233. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Patient-centered care is gaining widespread acceptance by the medical and lay communities and is increasingly recognized as a goal of high-quality health care delivery. Patient-centered care is based on ethical principles and aims at establishing a partnership between the health care team and patient, family member, or both in the care planning and decision-making process. Patient-centered care involves providing respectful care by tailoring management decisions to patients' beliefs, preferences, and values. A collaborative care approach can enhance patient engagement, foster shared decision-making that aligns with patient values and goals, promote more personalized and effective cardiovascular care, and potentially improve patient outcomes. The objective of this scientific statement is to inform health care professionals and stakeholders about the role and impact of patient-centered care in adult cardiovascular medicine. This scientific statement describes the background and rationale for patient-centered care in cardiovascular medicine, provides insight into patient-oriented medication management and patient-reported outcome measures, highlights opportunities and strategies to overcome challenges in patient-centered care, and outlines knowledge gaps and future directions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38602110/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38602110</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001233>10.1161/CIR.0000000000001233</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38602110</guid>
<pubDate>Thu, 11 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael J Goldfarb</dc:creator>
<dc:creator>Martha Abshire Saylor</dc:creator>
<dc:creator>Biykem Bozkurt</dc:creator>
<dc:creator>Jillianne Code</dc:creator>
<dc:creator>Katherine E Di Palo</dc:creator>
<dc:creator>Angela Durante</dc:creator>
<dc:creator>Kristin Flanary</dc:creator>
<dc:creator>Ruth Masterson Creber</dc:creator>
<dc:creator>Modele O Ogunniyi</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:creator>Martha Gulati</dc:creator>
<dc:creator>American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Council on Quality of Care and Outcomes Research</dc:creator>
<dc:date>2024-04-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Patient-Centered Adult Cardiovascular Care: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38602110</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001233</dc:identifier>
</item>
<item>
<title>Cardiovascular disease and cancer: shared risk factors and mechanisms</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38600368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular disease (CVD) and cancer are among the leading causes of morbidity and mortality globally, and these conditions are increasingly recognized to be fundamentally interconnected. In this Review, we present the current epidemiological data for each of the modifiable risk factors shared by the two diseases, including hypertension, hyperlipidaemia, diabetes mellitus, obesity, smoking, diet, physical activity and the social determinants of health. We then review the epidemiological data...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Apr 10. doi: 10.1038/s41569-024-01017-x. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular disease (CVD) and cancer are among the leading causes of morbidity and mortality globally, and these conditions are increasingly recognized to be fundamentally interconnected. In this Review, we present the current epidemiological data for each of the modifiable risk factors shared by the two diseases, including hypertension, hyperlipidaemia, diabetes mellitus, obesity, smoking, diet, physical activity and the social determinants of health. We then review the epidemiological data demonstrating the increased risk of CVD in patients with cancer, as well as the increased risk of cancer in patients with CVD. We also discuss the shared mechanisms implicated in the development of these conditions, highlighting their inherent bidirectional relationship. We conclude with a perspective on future research directions for the field of cardio-oncology to advance the care of patients with CVD and cancer.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38600368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38600368</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01017-x>10.1038/s41569-024-01017-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38600368</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicholas S Wilcox</dc:creator>
<dc:creator>Uri Amit</dc:creator>
<dc:creator>Jacob B Reibel</dc:creator>
<dc:creator>Eva Berlin</dc:creator>
<dc:creator>Kendyl Howell</dc:creator>
<dc:creator>Bonnie Ky</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cardiovascular disease and cancer: shared risk factors and mechanisms</dc:title>
<dc:identifier>pmid:38600368</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01017-x</dc:identifier>
</item>
<item>
<title>Canonical and non-canonical roles of complement in atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38600367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular diseases are the leading cause of death globally, and atherosclerosis is the major contributor to the development and progression of cardiovascular diseases. Immune responses have a central role in the pathogenesis of atherosclerosis, with the complement system being an acknowledged contributor. Chronic activation of liver-derived and serum-circulating canonical complement sustains endothelial inflammation and innate immune cell activation, and deposition of complement activation...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Apr 10. doi: 10.1038/s41569-024-01016-y. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular diseases are the leading cause of death globally, and atherosclerosis is the major contributor to the development and progression of cardiovascular diseases. Immune responses have a central role in the pathogenesis of atherosclerosis, with the complement system being an acknowledged contributor. Chronic activation of liver-derived and serum-circulating canonical complement sustains endothelial inflammation and innate immune cell activation, and deposition of complement activation fragments on inflamed endothelial cells is a hallmark of atherosclerotic plaques. However, increasing evidence indicates that liver-independent, cell-autonomous and non-canonical complement activities are underappreciated contributors to atherosclerosis. Furthermore, complement activation can also have atheroprotective properties. These specific detrimental or beneficial contributions of the complement system to the pathogenesis of atherosclerosis are dictated by the location of complement activation and engagement of its canonical versus non-canonical functions in a temporal fashion during atherosclerosis progression. In this Review, we summarize the classical and the emerging non-classical roles of the complement system in the pathogenesis of atherosclerosis and discuss potential strategies for therapeutic modulation of complement for the prevention and treatment of atherosclerotic cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38600367/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38600367</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01016-y>10.1038/s41569-024-01016-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38600367</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Pasquale Maffia</dc:creator>
<dc:creator>Claudio Mauro</dc:creator>
<dc:creator>Ayden Case</dc:creator>
<dc:creator>Claudia Kemper</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Canonical and non-canonical roles of complement in atherosclerosis</dc:title>
<dc:identifier>pmid:38600367</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01016-y</dc:identifier>
</item>
<item>
<title>Discordant Aortic Stenosis Parameters in Real-World Data: Do Not Ignore a Low Aortic Valve Area</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599723/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):e153. doi: 10.1016/j.jacc.2023.12.041.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599723/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599723</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.041>10.1016/j.jacc.2023.12.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599723</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew D Solomon</dc:creator>
<dc:creator>Anthony Demaria</dc:creator>
<dc:creator>Rick Nishimura</dc:creator>
<dc:creator>Femi Philip</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Discordant Aortic Stenosis Parameters in Real-World Data: Do Not Ignore a Low Aortic Valve Area</dc:title>
<dc:identifier>pmid:38599723</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.041</dc:identifier>
</item>
<item>
<title>Treatment and Prognosis of Less Than Severe Aortic Stenosis: The Importance of Context</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599722/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):e151. doi: 10.1016/j.jacc.2023.12.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599722/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599722</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.042>10.1016/j.jacc.2023.12.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599722</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Wael A Jaber</dc:creator>
<dc:creator>L Leonardo Rodriguez</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Treatment and Prognosis of Less Than Severe Aortic Stenosis: The Importance of Context</dc:title>
<dc:identifier>pmid:38599722</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.042</dc:identifier>
</item>
<item>
<title>Effect of Personalized Accelerated Pacing in Patients With Nonobstructive Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599721/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1492-1493. doi: 10.1016/j.jacc.2024.01.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599721/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599721</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.036>10.1016/j.jacc.2024.01.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599721</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Sana Riaz</dc:creator>
<dc:creator>Sean R McMahon</dc:creator>
<dc:creator>Katherine Stockey</dc:creator>
<dc:creator>Markus Meyer</dc:creator>
<dc:creator>Adaya Weissler-Snir</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Personalized Accelerated Pacing in Patients With Nonobstructive Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38599721</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.036</dc:identifier>
</item>
<item>
<title>Realizing Our Vision: ACC's Next 5-Year Strategic Plan</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599720/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1489-1491. doi: 10.1016/j.jacc.2024.03.366.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599720/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599720</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.366>10.1016/j.jacc.2024.03.366</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599720</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Cathleen Biga</dc:creator>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Realizing Our Vision: ACC's Next 5-Year Strategic Plan</dc:title>
<dc:identifier>pmid:38599720</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.366</dc:identifier>
</item>
<item>
<title>Recent Insights Into Native Valve Infective Endocarditis: JACC Focus Seminar 4/4</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599719/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>This focused review highlights the latest issues in native valve infective endocarditis. Native valve disease moderately increases the risk of developing infective endocarditis. In 2023, new diagnostic criteria were published by the Duke-International Society of Cardiovascular Infectious Diseases group. New pathogens were designated as typical, and findings on computed tomography imaging were included as diagnostic criteria. It is now recognized that a multidisciplinary approach to care is...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1431-1443. doi: 10.1016/j.jacc.2023.12.043.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This focused review highlights the latest issues in native valve infective endocarditis. Native valve disease moderately increases the risk of developing infective endocarditis. In 2023, new diagnostic criteria were published by the Duke-International Society of Cardiovascular Infectious Diseases group. New pathogens were designated as typical, and findings on computed tomography imaging were included as diagnostic criteria. It is now recognized that a multidisciplinary approach to care is vital, and the role of an "endocarditis team" is highlighted. Recent studies have suggested that a transition from intravenous to oral antibiotics in selected patients may be reasonable, and the role of long-acting antibiotics is discussed. It is also now clear that an aggressive surgical approach can be life-saving in some patients. Finally, results of several recent studies have suggested there is an association between dental and other invasive procedures and an increased risk of developing infective endocarditis. Moreover, data indicate that antibiotic prophylaxis may be effective in some scenarios.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599719/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599719</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.043>10.1016/j.jacc.2023.12.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599719</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Mark J Dayer</dc:creator>
<dc:creator>Juan A Quintero-Martinez</dc:creator>
<dc:creator>Martin H Thornhill</dc:creator>
<dc:creator>John B Chambers</dc:creator>
<dc:creator>Gosta B Pettersson</dc:creator>
<dc:creator>Larry M Baddour</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Recent Insights Into Native Valve Infective Endocarditis: JACC Focus Seminar 4/4</dc:title>
<dc:identifier>pmid:38599719</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.043</dc:identifier>
</item>
<item>
<title>The Clinical Challenge of Prosthetic Valve Endocarditis: JACC Focus Seminar 3/4</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>During the past 6 decades, there have been numerous changes in prosthetic valve endocarditis (PVE), currently affecting an older population and increasing in incidence in patients with transcatheter-implanted valves. Significant microbiologic (molecular biology) and imaging diagnostic (fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography) advances have been incorporated into the 2023 Duke-International Society for Cardiovascular Infectious Diseases infective...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1418-1430. doi: 10.1016/j.jacc.2024.01.037.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">During the past 6 decades, there have been numerous changes in prosthetic valve endocarditis (PVE), currently affecting an older population and increasing in incidence in patients with transcatheter-implanted valves. Significant microbiologic (molecular biology) and imaging diagnostic (fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography) advances have been incorporated into the 2023 Duke-International Society for Cardiovascular Infectious Diseases infective endocarditis diagnostic criteria, thus increasing the diagnostic sensitivity for PVE without sacrificing specificity in validation studies. PVE is a life-threatening disease requiring management by multidisciplinary endocarditis teams in cardiac centers to improve outcomes. Novel surgical options are now available, and an increasing set of patients may avoid surgical intervention despite indication. Selected patients may complete parenteral or oral antimicrobial treatment at home. Finally, patients with prosthetic valves implanted surgically or by the transcatheter approach are candidates for antibiotic prophylaxis before invasive dental procedures.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599718</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.037>10.1016/j.jacc.2024.01.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599718</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Guillermo Cuervo</dc:creator>
<dc:creator>Eduard Quintana</dc:creator>
<dc:creator>Ander Regueiro</dc:creator>
<dc:creator>Andrés Perissinotti</dc:creator>
<dc:creator>Barbara Vidal</dc:creator>
<dc:creator>Jose M Miro</dc:creator>
<dc:creator>Larry M Baddour</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Clinical Challenge of Prosthetic Valve Endocarditis: JACC Focus Seminar 3/4</dc:title>
<dc:identifier>pmid:38599718</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.037</dc:identifier>
</item>
<item>
<title>Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1415-1417. doi: 10.1016/j.jacc.2024.03.002. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599717</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.002>10.1016/j.jacc.2024.03.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599717</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Luke J Burchill</dc:creator>
<dc:creator>C Charles Jain</dc:creator>
<dc:creator>William R Miranda</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure</dc:title>
<dc:identifier>pmid:38599717</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.002</dc:identifier>
</item>
<item>
<title>SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599716/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1399-1402. doi: 10.1016/j.jacc.2024.02.028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599716/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599716</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.028>10.1016/j.jacc.2024.02.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599716</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic</dc:title>
<dc:identifier>pmid:38599716</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.028</dc:identifier>
</item>
<item>
<title>Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599715/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Physiological-adaptive water conservation eliminated the expected osmotic diuretic potential of dapagliflozin and thereby prevented a glucose-driven increase in urine volume of approximately 10 mL/kg/d · 75 kg = 750 mL/kg/d. (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment [DAPA-Shuttle1]; NCT04080518).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1386-1398. doi: 10.1016/j.jacc.2024.02.020.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sodium-glucose cotransporter 2 inhibitors are believed to improve cardiac outcomes due to their osmotic diuretic potential.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to test the hypothesis that vasopressin-driven urine concentration overrides the osmotic diuretic effect of glucosuria induced by dapagliflozin treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: DAPA-Shuttle1 (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment) was a single-center, double-blind, randomized, placebo-controlled trial, in which patients with chronic heart failure NYHA functional classes I/II and reduced ejection fraction were randomly assigned to receive dapagliflozin 10 mg daily or placebo (1:1) for 4 weeks. The primary endpoint was change from baseline in urine osmolyte concentration. Secondary endpoints included changes in copeptin levels and solute free water clearance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Thirty-three randomized, sodium-glucose cotransporter 2 inhibitor-naïve participants completed the study, 29 of whom (placebo: n = 14; dapagliflozin: n = 15) provided accurate 24-hour urine collections (mean age 59 ± 14 years; left ventricular ejection fraction 31% ± 9%). Dapagliflozin treatment led to an isolated increase in urine glucose excretion by 3.3 mmol/kg/d (95% CI: 2.51-4.04; P &lt; 0.0001) within 48 hours (early) which persisted after 4 weeks (late; 2.7 mmol/kg/d [95% CI: 1.98-3.51]; P &lt; 0.0001). Dapagliflozin treatment increased serum copeptin early (5.5 pmol/L [95% CI: 0.45-10.5]; P &lt; 0.05) and late (7.8 pmol/L [95% CI: 2.77-12.81]; P &lt; 0.01), leading to proportional reductions in free water clearance (early: -9.1 mL/kg/d [95% CI: -14 to -4.12; P &lt; 0.001]; late: -11.0 mL/kg/d [95% CI: -15.94 to -6.07; P &lt; 0.0001]) and elevated urine concentrations (late: 134 mmol/L [95% CI: 39.28-229.12]; P &lt; 0.01). Therefore, urine volume did not significantly increase with dapagliflozin (mean difference early: 2.8 mL/kg/d [95% CI: -1.97 to 7.48; P = 0.25]; mean difference late: 0.9 mL/kg/d [95% CI: -3.83 to 5.62]; P = 0.70).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Physiological-adaptive water conservation eliminated the expected osmotic diuretic potential of dapagliflozin and thereby prevented a glucose-driven increase in urine volume of approximately 10 mL/kg/d · 75 kg = 750 mL/kg/d. (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment [DAPA-Shuttle1]; NCT04080518).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599715/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599715</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.020>10.1016/j.jacc.2024.02.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599715</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Adriana Marton</dc:creator>
<dc:creator>Seyed Ehsan Saffari</dc:creator>
<dc:creator>Manfred Rauh</dc:creator>
<dc:creator>Ruo-Ning Sun</dc:creator>
<dc:creator>Armin M Nagel</dc:creator>
<dc:creator>Peter Linz</dc:creator>
<dc:creator>Tzy Tiing Lim</dc:creator>
<dc:creator>Kaoru Takase-Minegishi</dc:creator>
<dc:creator>Anastacia Pajarillaga</dc:creator>
<dc:creator>Sharon Saw</dc:creator>
<dc:creator>Norihiko Morisawa</dc:creator>
<dc:creator>Wan Keat Yam</dc:creator>
<dc:creator>Shintaro Minegishi</dc:creator>
<dc:creator>John J Totman</dc:creator>
<dc:creator>Serena Teo</dc:creator>
<dc:creator>Louis L Y Teo</dc:creator>
<dc:creator>Choon Ta Ng</dc:creator>
<dc:creator>Kento Kitada</dc:creator>
<dc:creator>Johannes Wild</dc:creator>
<dc:creator>Jean-Paul Kovalik</dc:creator>
<dc:creator>Friedrich C Luft</dc:creator>
<dc:creator>Peter J Greasley</dc:creator>
<dc:creator>Calvin W L Chin</dc:creator>
<dc:creator>David K L Sim</dc:creator>
<dc:creator>Jens Titze</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure</dc:title>
<dc:identifier>pmid:38599715</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.020</dc:identifier>
</item>
<item>
<title>Modulation of Antiplatelet Therapy in PCI-Treated Patients: A Rocky Road Toward More Individualized Treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1382-1385. doi: 10.1016/j.jacc.2024.03.355.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599714</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.355>10.1016/j.jacc.2024.03.355</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599714</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Dirk Sibbing</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Modulation of Antiplatelet Therapy in PCI-Treated Patients: A Rocky Road Toward More Individualized Treatment</dc:title>
<dc:identifier>pmid:38599714</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.355</dc:identifier>
</item>
<item>
<title>Effectiveness of Clopidogrel vs Alternative P2Y&lt;sub>;12&lt;/sub>; Inhibitors Based on the ABCD-GENE Score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These data support the use of alternative therapy over clopidogrel in CYP2C19 LOF allele carriers after PCI, regardless of ABCD-GENE score, while clopidogrel is as effective as alternative therapy in non-LOF patients with scores &lt;10.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1370-1381. doi: 10.1016/j.jacc.2024.02.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: An ABCD-GENE (age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genetic variants) score ≥10 predicts reduced clopidogrel effectiveness, but its association with response to alternative therapy remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to evaluate the association between ABCD-GENE score and the effectiveness of clopidogrel vs alternative P2Y<sub>12</sub> inhibitor (prasugrel or ticagrelor) therapy after percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 4,335 patients who underwent PCI, CYP2C19 genotyping, and P2Y<sub>12</sub> inhibitor treatment were included. The primary outcome was major atherothrombotic events (MAE) within 1 year after PCI. Cox regression was performed to assess event risk in clopidogrel-treated (reference) vs alternatively treated patients, with stabilized inverse probability weights derived from exposure propensity scores after stratifying by ABCD-GENE score and further by CYP2C19 loss-of-function (LOF) genotype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among patients with scores &lt;10 (n = 3,200), MAE was not different with alternative therapy vs clopidogrel (weighted HR: 0.89; 95% CI: 0.65-1.22; P = 0.475). The risk for MAE also did not significantly differ by treatment among patients with scores ≥10 (n = 1,135; weighted HR: 0.75; 95% CI: 0.51-1.11; P = 0.155). Among CYP2C19 LOF allele carriers, MAE risk appeared lower with alternative therapy in both the group with scores &lt;10 (weighted HR: 0.50; 95% CI: 0.25-1.01; P = 0.052) and the group with scores ≥10 (weighted HR: 0.48; 95% CI: 0.29-0.80; P = 0.004), while there was no difference in the group with scores &lt;10 and no LOF alleles (weighted HR: 1.03; 95% CI: 0.70-1.51; P = 0.885).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These data support the use of alternative therapy over clopidogrel in CYP2C19 LOF allele carriers after PCI, regardless of ABCD-GENE score, while clopidogrel is as effective as alternative therapy in non-LOF patients with scores &lt;10.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599713</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.015>10.1016/j.jacc.2024.02.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599713</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Cameron D Thomas</dc:creator>
<dc:creator>Francesco Franchi</dc:creator>
<dc:creator>Joseph S Rossi</dc:creator>
<dc:creator>Ellen C Keeley</dc:creator>
<dc:creator>R David Anderson</dc:creator>
<dc:creator>Amber L Beitelshees</dc:creator>
<dc:creator>Julio D Duarte</dc:creator>
<dc:creator>Luis Ortega-Paz</dc:creator>
<dc:creator>Yan Gong</dc:creator>
<dc:creator>Richard A Kerensky</dc:creator>
<dc:creator>Natasha Kulick</dc:creator>
<dc:creator>Caitrin W McDonough</dc:creator>
<dc:creator>Anh B Nguyen</dc:creator>
<dc:creator>Yehua Wang</dc:creator>
<dc:creator>Marshall Winget</dc:creator>
<dc:creator>William E Yang</dc:creator>
<dc:creator>Julie A Johnson</dc:creator>
<dc:creator>Almut G Winterstein</dc:creator>
<dc:creator>George A Stouffer</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Craig R Lee</dc:creator>
<dc:creator>Larisa H Cavallari</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effectiveness of Clopidogrel vs Alternative P2Y&lt;sub>;12&lt;/sub>; Inhibitors Based on the ABCD-GENE Score</dc:title>
<dc:identifier>pmid:38599713</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.015</dc:identifier>
</item>
<item>
<title>Unlocking the Gates of ISCHEMIA: Moving Toward Personalized Angina Management for Chronic Coronary Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599712/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1367-1369. doi: 10.1016/j.jacc.2024.03.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599712/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599712</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.001>10.1016/j.jacc.2024.03.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599712</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Josip Andelo Borovac</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Unlocking the Gates of ISCHEMIA: Moving Toward Personalized Angina Management for Chronic Coronary Syndrome</dc:title>
<dc:identifier>pmid:38599712</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.001</dc:identifier>
</item>
<item>
<title>Variation in Health Status With Invasive vs Conservative Management of Chronic Coronary Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38599711/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240411222019&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the management of chronic coronary disease, individual patient characteristics are associated with 1-year health status, with younger age and poorer angina-related health status showing greater benefit from invasive management. This prediction algorithm can support the translation of the ISCHEMIA trial results to individual patients. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 16;83(15):1353-1366. doi: 10.1016/j.jacc.2024.02.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The ISCHEMIA trial found that patients with chronic coronary disease randomized to invasive strategy had better health status than those randomized to conservative strategy. It is unclear how best to translate these population-level results to individual patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to identify patient characteristics associated with health status from invasive and conservative strategies, and develop a prediction algorithm for shared decision-making.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: One-year disease-specific health status was assessed in ISCHEMIA with the Seattle Angina Questionnaire (SAQ) Summary Score (SAQ SS) and Angina Frequency, Physical Limitations (PL), and Quality of Life (QL) domains (range 0-100, higher = less angina/better health status).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4,617 patients from 320 sites in 37 countries, mean SAQ SS was 74.1 ± 18.9 at baseline and 85.7 ± 15.6 at 1 year. Lower baseline SAQ SS and younger age were associated with better 1-year health status with invasive strategy (P interaction = 0.009 and P interaction = 0.004, respectively). For the individual domains, there were significant treatment interactions for baseline SAQ score (Angina Frequency, PL), age (PL, QL), anterior ischemia (PL), and number of baseline antianginal medications (QL), with more benefit of invasive in patients with worse baseline health status, younger age, anterior ischemia, and on more antianginal medications. Parsimonious prediction models were developed for 1-year SAQ domains with invasive or conservative strategies to support shared decision-making.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the management of chronic coronary disease, individual patient characteristics are associated with 1-year health status, with younger age and poorer angina-related health status showing greater benefit from invasive management. This prediction algorithm can support the translation of the ISCHEMIA trial results to individual patients. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38599711/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240411222019&v=2.18.0.post9+e462414">38599711</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.019>10.1016/j.jacc.2024.02.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38599711</guid>
<pubDate>Wed, 10 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Philip G Jones</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Daniel B Mark</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>Jiyan Chen</dc:creator>
<dc:creator>Jonathan D Newman</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>ISCHEMIA Research Group</dc:creator>
<dc:date>2024-04-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Variation in Health Status With Invasive vs Conservative Management of Chronic Coronary Disease</dc:title>
<dc:identifier>pmid:38599711</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.019</dc:identifier>
</item>





























</channel>
</rss>